Andere talen Asarina Pharma AB

Aandelen

ASAP

SE0011641794

Beurs gesloten - Nasdaq Stockholm Andere beurzen 12:47:54 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,968 ^SEK	-1,22%		+7,56%	+10,00%

27/02	Asarina Pharma AB (publ) rapporteert resultaten voor het volledige jaar eindigend op 31 december 2023	CI
2023	Asarina Pharma AB (publ) rapporteert resultaten voor het halfjaar dat eindigde op 30 juni 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023	27/02
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB	30/11
Asarina Pharma updates on partnering and financials	16/11
Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)	23-08-23
Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23
ASARINA PHARMA - POSITIVE TOURETTE SYNDROME RESULTS TO BE PRESENTED AT ESSTS, 15TH EUROPEAN CONFERENCE ON TOURETTE SYNDROME AND TIC DISORDERS	24-05-23
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)	22-05-23
Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	08-05-23
Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	05-05-23
Asarina Pharma's Positive Phase IIa Tourette Syndrome Results to Be Presented At Ticcon, the Virtual National Conference of the Tourette Association of America	05-05-23
Asarina Pharma AB (publ) releases Annual Report 2022	01-05-23
Asarina Pharma AB (publ) releases Annual Report 2022	28-04-23
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)	18-04-23
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette syndrome	03-04-23
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome	01-04-23
Asarina Pharma AB (publ) releases Year-End Report 2022	27-02-23
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	27-02-23
Last Patient Last Visit for landmark Tourette Syndrome study	02-02-23
Asarina Pharma - Patient recruitment completed in landmark Tourette syndrome study	17-10-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Asarina Pharma AB

Aandelen

ASAP

SE0011641794

Andere talen

Filters